RU2206321C2 - Фармацевтическое средство, содержащее ингибитор rho-киназы - Google Patents
Фармацевтическое средство, содержащее ингибитор rho-киназы Download PDFInfo
- Publication number
- RU2206321C2 RU2206321C2 RU99104798/14A RU99104798A RU2206321C2 RU 2206321 C2 RU2206321 C2 RU 2206321C2 RU 99104798/14 A RU99104798/14 A RU 99104798/14A RU 99104798 A RU99104798 A RU 99104798A RU 2206321 C2 RU2206321 C2 RU 2206321C2
- Authority
- RU
- Russia
- Prior art keywords
- formula
- hydrogen
- alkyl
- isomer
- pharmaceutically acceptable
- Prior art date
Links
- 239000008177 pharmaceutical agent Substances 0.000 title claims abstract 11
- 239000003590 rho kinase inhibitor Substances 0.000 title claims 2
- 102000000568 rho-Associated Kinases Human genes 0.000 claims abstract 9
- 108010041788 rho-Associated Kinases Proteins 0.000 claims abstract 9
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract 2
- 206010020772 Hypertension Diseases 0.000 claims abstract 2
- 208000001132 Osteoporosis Diseases 0.000 claims abstract 2
- 208000017442 Retinal disease Diseases 0.000 claims abstract 2
- 206010038923 Retinopathy Diseases 0.000 claims abstract 2
- 230000001093 anti-cancer Effects 0.000 claims abstract 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract 2
- 208000006673 asthma Diseases 0.000 claims abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract 2
- 230000008602 contraction Effects 0.000 claims abstract 2
- 230000003836 peripheral circulation Effects 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 150000002431 hydrogen Chemical group 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 239000002253 acid Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- -1 nitro, amino Chemical group 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 150000002829 nitrogen Chemical group 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005945 imidazopyridyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 5
- 229940124597 therapeutic agent Drugs 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
Изобретение относится к медицине. Предложен ингибитор Rho-киназы в качестве нового фармацевтического агента, в частности в качестве терапевтического агента от гипертензии, стенокардии, супрессивного агента - от цереброваскулярного сокращения, терапевтического агента - от астмы, от нарушения периферического кровообращения, от артериосклероза, противоракового лекарственного средства, терапевтического агента - от остеопороза, терапевтического агента - от ретинопатии. Кроме того, ингибитор Rho-киназы используют в качестве реагента и диагностического средства. Изобретение обеспечивает расширение арсенала лекарственных средств. 11 с.п.ф-лы, 10 табл.
Description
Текст описания в факсимильном виде (см. чертежи). Т Т
Claims (11)
1. Ингибитор Rho-киназы, включающий амидное производное формулы (I)
где Ra - группа формулы
или
в формулах (а) и (b),
R обозначает водород, алкил или циклоалкил, циклоалкилалкил, фенил или аралкил, которые необязательно имеют заместитель на кольце, или группу формулы
где R6 обозначает водород, алкил или формулу - NR8R9, где R8 и R9 одинаковы или различны и каждый обозначает водород, алкил, аралкил или фенил;
R7 обозначает водород, алкил, аралкил, фенил, нитро или циано, или R6 и R7 в сочетании создают группу, образующую гетероцикл, необязательно имеющий в кольце атом кислорода, атом серы или необязательно замещенный атом азота;
R1 обозначает водород, алкил или циклоалкил, циклоалкилалкил, фенил или аралкил, которые необязательно имеют заместитель на кольце,
или R и R1 в сочетании образуют вместе с соседним атомом азота группу, образующую гетероцикл, необязательно имеющий в кольце атом кислорода, атом серы или необязательно замещенный атом азота;
R2 обозначает водород или алкил;
R3 и R4 одинаковы или различны и каждый обозначает водород, алкил, аралкил, галоген, нитро, амино, алкиламино, ациламино, гидрокси, алкокси, аралкилокси, циано, ацил, меркапто, алкилтио, аралкилтио, карбокси, алкоксикарбонил, карбамоил, алкилкарбамоил или азид;
А обозначает группу формулы
где R10 и R11 одинаковы или различны и каждый обозначает водород, алкил, галогеналкил, аралкил, гидроксиалкил, карбокси или алкоксикарбонил, или R10 и R11 создают группу, которая образует циклоалкил в сочетании;
1, m и n обозначают каждый 0 или целое число 1-3,
в формуле (с):
L обозначает водород алкил, аминоалкил, моно- или диалкиламиноалкил, тетрагидрофурфурил, карбамоилалкил, фталимидоалкил, амидино или группу формулы
или
где В обозначает водород, алкил, алкокси, аралкил, аралкилокси, аминоалкил, гидроксиалкил, алканоилоксиалкил, алкоксикарбонилалкил, α-аминобензил, фурил, пиридил, фенил, фениламино, стирил или имидазопиридил;
Q1 обозначает водород, галоген, гидрокси, аралкилокси или тиенилметил;
W обозначает алкилен;
Q2 обозначает водород, галоген, гидрокси или аралкилокси
X обозначает алкилен,
Q3 обозначает водород, галоген, гидрокси, алкокси, нитро, амино, 2,3-дигидрофурил или 5-метил-3-оксо-2,3,4,5-тетрагидропиридазин-6-ил;
Y обозначает ординарную связь, алкилен или алкенилен,
в формуле (с):
пунктирная линия обозначает ординарную связь или двойную связь;
R5 обозначает водород, гидрокси, алкокси, алкоксикарбонилокси, алканоилокси или аралкилоксикарбонилокси;
Rb обозначает водород, алкил, аралкил, аминоалкил или моно- или диалкиламиноалкил;
Rс обозначает необязательно замещенный гетероцикл, содержащий азот;
или его изомер и/или его фармацевтически приемлемую кислотно-аддитивную соль.
где Ra - группа формулы
или
в формулах (а) и (b),
R обозначает водород, алкил или циклоалкил, циклоалкилалкил, фенил или аралкил, которые необязательно имеют заместитель на кольце, или группу формулы
где R6 обозначает водород, алкил или формулу - NR8R9, где R8 и R9 одинаковы или различны и каждый обозначает водород, алкил, аралкил или фенил;
R7 обозначает водород, алкил, аралкил, фенил, нитро или циано, или R6 и R7 в сочетании создают группу, образующую гетероцикл, необязательно имеющий в кольце атом кислорода, атом серы или необязательно замещенный атом азота;
R1 обозначает водород, алкил или циклоалкил, циклоалкилалкил, фенил или аралкил, которые необязательно имеют заместитель на кольце,
или R и R1 в сочетании образуют вместе с соседним атомом азота группу, образующую гетероцикл, необязательно имеющий в кольце атом кислорода, атом серы или необязательно замещенный атом азота;
R2 обозначает водород или алкил;
R3 и R4 одинаковы или различны и каждый обозначает водород, алкил, аралкил, галоген, нитро, амино, алкиламино, ациламино, гидрокси, алкокси, аралкилокси, циано, ацил, меркапто, алкилтио, аралкилтио, карбокси, алкоксикарбонил, карбамоил, алкилкарбамоил или азид;
А обозначает группу формулы
где R10 и R11 одинаковы или различны и каждый обозначает водород, алкил, галогеналкил, аралкил, гидроксиалкил, карбокси или алкоксикарбонил, или R10 и R11 создают группу, которая образует циклоалкил в сочетании;
1, m и n обозначают каждый 0 или целое число 1-3,
в формуле (с):
L обозначает водород алкил, аминоалкил, моно- или диалкиламиноалкил, тетрагидрофурфурил, карбамоилалкил, фталимидоалкил, амидино или группу формулы
или
где В обозначает водород, алкил, алкокси, аралкил, аралкилокси, аминоалкил, гидроксиалкил, алканоилоксиалкил, алкоксикарбонилалкил, α-аминобензил, фурил, пиридил, фенил, фениламино, стирил или имидазопиридил;
Q1 обозначает водород, галоген, гидрокси, аралкилокси или тиенилметил;
W обозначает алкилен;
Q2 обозначает водород, галоген, гидрокси или аралкилокси
X обозначает алкилен,
Q3 обозначает водород, галоген, гидрокси, алкокси, нитро, амино, 2,3-дигидрофурил или 5-метил-3-оксо-2,3,4,5-тетрагидропиридазин-6-ил;
Y обозначает ординарную связь, алкилен или алкенилен,
в формуле (с):
пунктирная линия обозначает ординарную связь или двойную связь;
R5 обозначает водород, гидрокси, алкокси, алкоксикарбонилокси, алканоилокси или аралкилоксикарбонилокси;
Rb обозначает водород, алкил, аралкил, аминоалкил или моно- или диалкиламиноалкил;
Rс обозначает необязательно замещенный гетероцикл, содержащий азот;
или его изомер и/или его фармацевтически приемлемую кислотно-аддитивную соль.
2. Фармацевтический агент, включающий эффективное количество соединения формулы (I), его изомера и/или его фармацевтически приемлемой кислотно-аддитивной соли для лечения гипертензии, обусловленной Rho-киназой.
3. Фармацевтический агент, включающий эффективное количество соединения формулы (I), его изомера и/или его фармацевтически приемлемой кислотно-аддитивной соли для лечения стенокардии, обусловленной Rho-киназой.
4. Фармацевтический агент, включающий соединение формулы (I), его изомер и/или его фармацевтически приемлемую кислотно-аддитивную соль для подавления цереброваскулярного сокращения, обусловленного Rho-киназой.
5. Фармацевтический агент, включающий эффективное количество соединения формулы (I), его изомера и/или фармацевтически приемлемой кислотно-аддитивной соли для лечения астмы, обусловленной Rho-киназой.
6. Фармацевтический агент, включающий эффективное количество соединения формулы (I), его изомера и/или его фармацевтически приемлемой кислотно-аддитивной соли для лечения нарушения периферического кровообращения, обусловленного Rho-киназой.
7. Фармацевтический агент, включающий эффективное количество соединения формулы (I), его изомера и/или его фармацевтически приемлемой кислотно-аддитивной соли для лечения артериосклероза, обусловленного Rho-киназой.
8. Фармацевтический агент, включающий эффективное количество соединения формулы (I), его изомера и/или его фармацевтически приемлемой кислотно-аддитивной соли, обладающий противораковым действием.
9. Фармацевтический агент, включающий эффективное количество соединения формулы (I), его изомера и/или его фармацевтически приемлемой кислотно-аддитивной соли для лечения остеопороза.
10. Фармацевтический агент, включающий эффективное количество соединения формулы (I), его изомера и/или его фармацевтически приемлемой кислотно-аддитивной соли для лечения ретинопатии.
11. Реагент, обладающий активностью, ингибирующей Rho-киназу в образце, включающий соединение формулы (I), его изомер и/или его фармацевтически приемлемую кислотно-аддитивную соль.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8/212409 | 1996-08-12 | ||
| JP21240996 | 1996-08-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU99104798A RU99104798A (ru) | 2001-01-27 |
| RU2206321C2 true RU2206321C2 (ru) | 2003-06-20 |
Family
ID=16622116
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU99104798/14A RU2206321C2 (ru) | 1996-08-12 | 1997-08-08 | Фармацевтическое средство, содержащее ингибитор rho-киназы |
| RU2003103606/15A RU2003103606A (ru) | 1996-08-12 | 2003-02-06 | Фармацевтическое средство, содержащее ингибитор rho-киназы |
| RU2003104284/15A RU2003104284A (ru) | 1996-08-12 | 2003-02-12 | Фармацевтическое средство, содержащее ингибитор rho-киназы |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003103606/15A RU2003103606A (ru) | 1996-08-12 | 2003-02-06 | Фармацевтическое средство, содержащее ингибитор rho-киназы |
| RU2003104284/15A RU2003104284A (ru) | 1996-08-12 | 2003-02-12 | Фармацевтическое средство, содержащее ингибитор rho-киназы |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US6218410B1 (ru) |
| EP (1) | EP0956865B2 (ru) |
| JP (1) | JP3669711B2 (ru) |
| KR (2) | KR100595740B1 (ru) |
| CN (1) | CN100389828C (ru) |
| AT (1) | ATE359822T1 (ru) |
| AU (1) | AU738620B2 (ru) |
| BG (4) | BG63992B1 (ru) |
| BR (1) | BR9711154A (ru) |
| CA (1) | CA2263425C (ru) |
| CZ (1) | CZ301044B6 (ru) |
| DE (1) | DE69737631T3 (ru) |
| DK (1) | DK0956865T4 (ru) |
| EE (1) | EE9900050A (ru) |
| ES (1) | ES2286834T5 (ru) |
| HK (1) | HK1022436A1 (ru) |
| HU (1) | HU229864B1 (ru) |
| IL (1) | IL128456A0 (ru) |
| IS (1) | IS4973A (ru) |
| NO (1) | NO990622L (ru) |
| NZ (2) | NZ513800A (ru) |
| PL (1) | PL331561A1 (ru) |
| PT (1) | PT956865E (ru) |
| RU (3) | RU2206321C2 (ru) |
| SI (1) | SI0956865T2 (ru) |
| WO (1) | WO1998006433A1 (ru) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8357693B2 (en) | 2005-03-25 | 2013-01-22 | Surface Logix, Inc. | Pharmacokinetically improved compounds |
| US11384051B2 (en) | 2015-06-24 | 2022-07-12 | Nitto Denko Corporation | Ionizable compounds and compositions and uses thereof |
| RU2776478C2 (ru) * | 2015-06-24 | 2022-07-21 | Нитто Денко Корпорейшн | Ионизируемые соединения и композиции и их применения |
Families Citing this family (199)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0956865B2 (en) | 1996-08-12 | 2010-08-18 | Mitsubishi Tanabe Pharma Corporation | MEDICINES COMPRISING Rho KINASE INHIBITOR |
| US20080233098A1 (en) * | 1997-10-31 | 2008-09-25 | Mckerracher Lisa | RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth |
| EP1074545A4 (en) * | 1998-04-23 | 2001-08-22 | Hiroyoshi Hidaka | ISOCHINOLINE SULPHONAMIDE DERIVATIVES AND MEDICINES CONTAINING IT AS AN ACTIVE INGREDIENT |
| EP1459742B9 (en) * | 1998-08-17 | 2012-05-02 | Senju Pharmaceutical Co., Ltd. | Agent for prophylaxis and treatment of asthenopia and pseudomyopia |
| US7169783B2 (en) * | 1998-11-02 | 2007-01-30 | Universite De Montreal | (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion |
| WO2000057914A1 (fr) * | 1999-03-25 | 2000-10-05 | Santen Pharmaceutical Co., Ltd. | Agents permettant d'abaisser la tension oculaire |
| CN1187090C (zh) | 1999-03-25 | 2005-02-02 | 三菱制药株式会社 | 间质性肺炎、肺纤维化症的预防和治疗药 |
| AU3987800A (en) * | 1999-04-22 | 2000-11-10 | Mitsubishi Pharma Corporation | Preventives/remedies for angiostenosis |
| ATE506967T1 (de) * | 1999-04-27 | 2011-05-15 | Mitsubishi Tanabe Pharma Corp | Arzneimittel zur präventiven oder therapeutische behandlung von lebererkrankungen |
| WO2000078351A1 (fr) * | 1999-06-18 | 2000-12-28 | Mitsubishi Pharma Corporation | Promoteurs de l'osteogenese |
| JP2001081031A (ja) * | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
| AU6865100A (en) * | 1999-09-02 | 2001-04-10 | Mitsubishi Pharma Corporation | Osteogenesis promoting agents |
| WO2001022997A1 (fr) * | 1999-09-29 | 2001-04-05 | Mitsubishi Pharma Corporation | Analgesiques |
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| DE60120138T8 (de) * | 2000-03-16 | 2007-10-11 | Mitsubishi Pharma Corp. | Amid-verbindungen und deren verwendung |
| AU2001236006A1 (en) * | 2000-03-31 | 2001-10-15 | Mitsubishi Pharma Corporation | Preventives/remedies for kidney diseases |
| CA2413313C (en) | 2000-06-23 | 2011-06-14 | Mitsubishi Pharma Corporation | Antitumor effect potentiators |
| PL359918A1 (en) * | 2000-09-20 | 2004-09-06 | Merck Patent Gmbh | 4-amino-quinazolines |
| AU2001293817A1 (en) * | 2000-09-20 | 2002-04-02 | Merck Patent Gmbh | 4-amino-quinazolines |
| JP4582561B2 (ja) * | 2000-10-23 | 2010-11-17 | 旭化成ファーマ株式会社 | 移植による血管病変の発生抑制剤 |
| JP2002139493A (ja) * | 2000-11-01 | 2002-05-17 | Sumitomo Pharmaceut Co Ltd | 新規なハイスループット・スクリーニング方法 |
| CA2325842C (en) * | 2000-11-02 | 2007-08-07 | Lisa Mckerracher | Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof |
| US20020177207A1 (en) * | 2001-03-14 | 2002-11-28 | Myriad Genetics, Incorporated | Tsg101-interacting proteins and use thereof |
| AU2002246924A1 (en) * | 2001-01-05 | 2002-07-16 | The Medical College Of Georgia Research Institute, Inc. | Treatment of erectile dysfunction with rho-kinase inhibitors |
| JP2002226375A (ja) * | 2001-01-31 | 2002-08-14 | Asahi Kasei Corp | 線維化予防、治療剤 |
| WO2002098370A2 (en) * | 2001-03-02 | 2002-12-12 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
| DE60218138T2 (de) * | 2001-03-23 | 2007-09-20 | Bayer Pharmaceuticals Corp., West Haven | Rho-kinase inhibitoren |
| CA2441492C (en) * | 2001-03-23 | 2011-08-09 | Bayer Corporation | Rho-kinase inhibitors |
| US7109208B2 (en) * | 2001-04-11 | 2006-09-19 | Senju Pharmaceutical Co., Ltd. | Visual function disorder improving agents |
| US7442686B2 (en) | 2001-04-12 | 2008-10-28 | Bioaxone Therapeutique Inc. | Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions |
| WO2002100833A1 (fr) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
| JP5042419B2 (ja) * | 2001-08-15 | 2012-10-03 | 旭化成ファーマ株式会社 | 骨形成促進剤および骨形成促進組成物 |
| US7829566B2 (en) * | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
| DE10153605A1 (de) * | 2001-11-02 | 2003-05-28 | Morphochem Ag Komb Chemie | Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens |
| WO2003047591A1 (en) * | 2001-11-30 | 2003-06-12 | Asahi Kasei Pharma Corporation | Remedies for primary pulmonary hypertension |
| FR2833840B1 (fr) * | 2001-12-21 | 2010-06-18 | Rytek | Methodes et compositions pour le traitement de pathologies respiratoires |
| AU2003202263A1 (en) * | 2002-01-10 | 2003-07-30 | Bayer Healthcare Ag | Roh-kinase inhibitors |
| CA2473510A1 (en) * | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
| MXPA04007196A (es) * | 2002-01-23 | 2005-06-08 | Bayer Pharmaceuticals Corp | Inhibidores de rho-quinasa. |
| US7645878B2 (en) * | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
| GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| WO2003082808A1 (fr) * | 2002-04-03 | 2003-10-09 | Sumitomo Pharmaceuticals Company, Limited. | Derives de benzamide |
| US20040028716A1 (en) * | 2002-06-14 | 2004-02-12 | Marks Andrew R. | Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| WO2004006947A1 (en) * | 2002-07-12 | 2004-01-22 | Yihai Cao | A method for inhibiting vascular permeability and tissue edema |
| AU2003281623B8 (en) * | 2002-07-22 | 2009-06-11 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivative |
| US7094789B2 (en) | 2002-07-22 | 2006-08-22 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivatives |
| DE10233737A1 (de) * | 2002-07-24 | 2004-02-05 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen |
| AU2003257960A1 (en) * | 2002-08-01 | 2004-03-03 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Cell modulation using a cytoskeletal protein |
| TWI350170B (en) | 2002-08-29 | 2011-10-11 | Santen Pharmaceutical Co Ltd | Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin |
| CA2400996A1 (en) * | 2002-09-03 | 2004-03-03 | Lisa Mckerracher | 1,4-substituted cyclohexane derivatives |
| WO2004024717A1 (ja) * | 2002-09-12 | 2004-03-25 | Kirin Beer Kabushiki Kaisha | キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬 |
| US20050215601A1 (en) * | 2002-09-25 | 2005-09-29 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient |
| US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| AU2003280812A1 (en) * | 2002-11-18 | 2004-06-15 | Santen Pharmaceutical Co., Ltd. | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER |
| AU2003901270A0 (en) * | 2003-03-18 | 2003-04-03 | Medvet Science Pty. Ltd. | A method of modulating muscle cell functioning |
| AU2004221792C1 (en) * | 2003-03-18 | 2009-09-24 | Medvet Science Pty. Ltd. | A method of modulating smooth muscle cell functioning by modulating sphingosine kinase mediated signalling |
| GB2400316A (en) * | 2003-04-10 | 2004-10-13 | Richard Markoll | Electromagnetic stimulation in patients with osteoporosis |
| US7354584B2 (en) | 2003-04-11 | 2008-04-08 | Medimmune, Inc. | Recombinant IL-9 antibodies |
| US20070093513A1 (en) * | 2003-04-18 | 2007-04-26 | Senju Pharmaceutical Co., Ltd. | Agent for repairing corneal perception |
| US20050014783A1 (en) * | 2003-05-29 | 2005-01-20 | Schering Aktiengesellschaft | Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
| US20110098232A1 (en) * | 2003-05-30 | 2011-04-28 | Zeilig Charles E | Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis |
| US7160894B2 (en) | 2003-06-06 | 2007-01-09 | Asahi Kasei Pharma Corporation | Tricyclic compound |
| WO2004108142A2 (en) * | 2003-06-06 | 2004-12-16 | The University Of Manchester | Inhibitors of tip-1 for treatment tissue damage |
| WO2005017160A2 (en) * | 2003-08-13 | 2005-02-24 | Children's Hospital Medical Center | Mobilization of hematopoietic cells |
| EP1656451A2 (en) | 2003-08-13 | 2006-05-17 | Children's Hospital Medical Center | Chimeric peptides for the regulation of gtpases |
| JP4934426B2 (ja) | 2003-08-18 | 2012-05-16 | メディミューン，エルエルシー | 抗体のヒト化 |
| US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
| US7371850B1 (en) * | 2003-08-20 | 2008-05-13 | Myriad Genetics, Inc. | Method and composition for reducing expression of ROCK-II |
| JP4110324B2 (ja) | 2003-10-15 | 2008-07-02 | 宇部興産株式会社 | 新規インダゾール誘導体 |
| WO2005056024A1 (en) * | 2003-12-05 | 2005-06-23 | Children's Hospital Medical Center | Methods of enhancing stem cell engraftment |
| PT1696920E (pt) | 2003-12-19 | 2015-01-14 | Plexxikon Inc | Compostos e métodos para o desenvolvimento de moduladores de ret |
| MXPA06006862A (es) * | 2003-12-22 | 2007-01-26 | Alcon Inc | Agentes para el tratamiento de la retinopatia diabetica y formacion de drusen en degeneracion macular. |
| AU2004308919B2 (en) * | 2003-12-22 | 2009-11-12 | Alcon, Inc. | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| WO2005080394A1 (en) * | 2004-02-24 | 2005-09-01 | Bioaxone Therapeutique Inc. | 4-substituted piperidine derivatives |
| WO2005094824A1 (en) * | 2004-03-25 | 2005-10-13 | East Carolina University | Methods of enhancing cancer therapy by protecting nerve cells |
| US20080096238A1 (en) * | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
| US20060115870A1 (en) * | 2004-03-30 | 2006-06-01 | Alcon, Inc. | High throughput assay for human Rho kinase activity |
| WO2005102345A1 (en) * | 2004-03-30 | 2005-11-03 | Alcon, Inc. | Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
| DK1734996T3 (da) | 2004-04-02 | 2013-06-10 | Univ California | Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin |
| KR101213766B1 (ko) * | 2004-06-03 | 2012-12-18 | 미쓰비시 타나베 파마 코퍼레이션 | 아미드 화합물을 포함하는 각막 민감도의 회복제 |
| WO2006047639A2 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| FR2879100B1 (fr) | 2004-12-09 | 2007-07-06 | Lionel Bueno | Compositions pour le traitement des pathologies oculaires de surface et de la retine |
| AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| EP1830853B1 (en) * | 2004-12-27 | 2011-08-10 | Novartis AG | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases |
| WO2006088088A1 (ja) * | 2005-02-16 | 2006-08-24 | Astellas Pharma Inc. | Ｒｏｃｋ阻害剤を含有する疼痛治療剤 |
| JP5153613B2 (ja) | 2005-03-18 | 2013-02-27 | メディミューン，エルエルシー | 抗体のフレームワーク・シャッフル |
| KR20080025174A (ko) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
| PL1899322T3 (pl) | 2005-06-28 | 2010-02-26 | Sanofi Aventis | Pochodne izochinoliny jako inhibitory kinazy Rho |
| CN101228132B (zh) | 2005-07-26 | 2012-10-10 | 塞诺菲-安万特股份有限公司 | 作为Rho-激酶抑制剂的环己基胺异喹啉酮衍生物 |
| WO2007012421A1 (en) | 2005-07-26 | 2007-02-01 | Sanofi-Aventis | Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| WO2007026664A1 (ja) | 2005-08-30 | 2007-03-08 | Asahi Kasei Pharma Corporation | スルホンアミド化合物 |
| CA2620818A1 (en) | 2005-09-02 | 2007-03-08 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| JP4832051B2 (ja) * | 2005-10-21 | 2011-12-07 | 学校法人順天堂 | 半月体形成性腎病変治療剤 |
| US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
| EP1951253A2 (en) | 2005-10-26 | 2008-08-06 | Cotherix, Inc. | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US7867999B1 (en) | 2005-12-22 | 2011-01-11 | Alcon Research, Ltd. | Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions |
| CA2629342A1 (en) * | 2005-12-22 | 2007-07-05 | Alcon Research, Ltd. | (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | アンジオテンシン調節による神経新生 |
| US8227480B2 (en) | 2006-06-08 | 2012-07-24 | Ube Industries, Ltd. | Indazole derivative having spiro ring structure in side chain |
| US20090247552A1 (en) * | 2006-07-31 | 2009-10-01 | Shirou Sawa | Aqueous liquid preparation containing amide compound |
| WO2008022182A1 (en) * | 2006-08-16 | 2008-02-21 | The Uab Research Foundation | Methods for promoting coupling between bone formation and resorption |
| CA2661782C (en) | 2006-08-28 | 2019-04-16 | La Jolla Institute For Allergy And Immunology | Antagonistic human light-specific human monoclonal antibodies |
| GB0617222D0 (en) * | 2006-08-31 | 2006-10-11 | Vereniging Het Nl Kanker I | Antibiotics |
| JP2010502722A (ja) | 2006-09-08 | 2010-01-28 | ブレインセルス，インコーポレイティド | ４−アシルアミノピリジン誘導体を含む組み合わせ |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2008049000A2 (en) * | 2006-10-18 | 2008-04-24 | United Therapeutics Corporation | Combination therapy for pulmonary arterial hypertension |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| WO2008079945A2 (en) * | 2006-12-20 | 2008-07-03 | University Of South Florida | Rock inhibitors and uses thereof |
| AR064420A1 (es) * | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
| BRPI0720859A2 (pt) | 2006-12-27 | 2014-03-25 | Sanofi Aventis | Derivados de isoquinolina e isoquinolinona substituídos com cicloalquilamina |
| RU2009128693A (ru) | 2006-12-27 | 2011-02-10 | Санофи-Авентис (Fr) | Замещенные производные изохинолина и изохинолинона |
| BRPI0721180A2 (pt) | 2006-12-27 | 2014-03-18 | Sanofi Aventis | Derivados de isoquinolina substituídos com cicloalquilamina |
| PT2132194E (pt) | 2006-12-27 | 2011-05-16 | Sanofi Aventis | Isoquinolinas substitu?das e sua utiliza??o como inibidores de rho-cinase |
| CA2673916C (en) | 2006-12-27 | 2015-02-17 | Sanofi-Aventis | Substituted isoquinolone and isoquinolinone derivatives as inhibitors of rho-kinase |
| MX2009005966A (es) | 2006-12-27 | 2009-06-15 | Sanofi Aventis | Derivados de isoquinolona sustituidos con cicloalquilamina. |
| US7892830B2 (en) * | 2007-01-17 | 2011-02-22 | Wisconsin Alumni Research Foundation | Clonal culture of human pluripotent stem cells |
| WO2008105058A1 (ja) | 2007-02-27 | 2008-09-04 | Asahi Kasei Pharma Corporation | スルホンアミド化合物 |
| US7964613B2 (en) | 2007-02-28 | 2011-06-21 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
| KR101566171B1 (ko) | 2007-03-09 | 2015-11-06 | 삼성전자 주식회사 | 디지털 저작권 관리 방법 및 장치 |
| KR101540823B1 (ko) | 2007-03-30 | 2015-07-30 | 메디뮨 엘엘씨 | 항체 제제 |
| EP2155769B1 (en) | 2007-05-04 | 2012-06-27 | Katholieke Universiteit Leuven KU Leuven Research & Development | Tissue degeneration protection |
| US8232292B2 (en) | 2007-07-02 | 2012-07-31 | Asahi Kasei Pharma Corporation | Sulfonamide compound and crystal thereof |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| KR20180031066A (ko) | 2007-08-29 | 2018-03-27 | 센주 세이야꾸 가부시키가이샤 | 각막 내피 세포 접착 촉진제 |
| CN102088853A (zh) * | 2008-05-12 | 2011-06-08 | 安内斯蒂克斯公司 | 改善学习和记忆的化合物 |
| PL2303845T3 (pl) | 2008-06-24 | 2014-03-31 | Sanofi Sa | Bi- i policykliczne podstawione pochodne izochinoliny i izochinolinonu jako inhibitory kinazy Rho |
| CN102131784B (zh) | 2008-06-24 | 2014-08-27 | 赛诺菲-安万特 | 作为rho激酶抑制剂的取代的异喹啉和异喹啉酮 |
| WO2009156099A1 (en) | 2008-06-24 | 2009-12-30 | Sanofi-Aventis | 6-substituted isoquinolines and isoquinolinones |
| JPWO2010010702A1 (ja) | 2008-07-24 | 2012-01-05 | 国立大学法人大阪大学 | 軸性近視の予防または治療剤 |
| BRPI0918045A2 (pt) * | 2008-09-18 | 2015-12-01 | Astellas Pharma Inc | compostos de carboxamida heterocíclicos |
| EP2177218A1 (en) | 2008-10-15 | 2010-04-21 | Medizinische Universität Wien | Regenerative therapy |
| EP2177510A1 (en) | 2008-10-17 | 2010-04-21 | Universität des Saarlandes | Allosteric protein kinase modulators |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN110269838A (zh) | 2009-04-03 | 2019-09-24 | 豪夫迈罗氏公司 | 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途 |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| WO2011021221A2 (en) | 2009-08-17 | 2011-02-24 | Reliance Life Sciences Pvt. Ltd. | Compositions for spinal cord injury |
| RU2012117719A (ru) | 2009-10-16 | 2013-11-27 | Зе Скрипс Ресеч Инститьют | Индукция плюрипотентных клеток |
| CA2780190C (en) | 2009-11-06 | 2020-05-05 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN102188697B (zh) * | 2010-03-03 | 2014-11-05 | 中国医学科学院药物研究所 | 重组人Rho激酶在制备药物中的应用 |
| US9782454B2 (en) | 2010-04-22 | 2017-10-10 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
| KR101975688B1 (ko) | 2010-12-22 | 2019-05-07 | 페이트 세러퓨틱스, 인코포레이티드 | 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼 |
| US9540443B2 (en) | 2011-01-26 | 2017-01-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
| LT2672967T (lt) | 2011-02-07 | 2018-12-10 | Plexxikon Inc. | Junginiai ir būdai skirti kinazės moduliavimui, ir jų indikacijos |
| AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
| EP2628482A1 (en) | 2012-02-17 | 2013-08-21 | Academisch Medisch Centrum | Rho kinase inhiitors for use in the treatment of neuroblastoma |
| WO2013167475A1 (en) * | 2012-05-08 | 2013-11-14 | Syddansk Universitet | Anabolic compounds for treating and preventing bone loss diseases |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| CN104812775B (zh) | 2012-07-25 | 2019-05-03 | 塞尔德克斯医疗公司 | 抗kit抗体及其用途 |
| EP2906598A1 (en) | 2012-10-09 | 2015-08-19 | Igenica Biotherapeutics, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
| EP2968469A4 (en) | 2013-03-15 | 2016-08-31 | Longevity Biotech Inc | PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME |
| CN105050600B (zh) | 2013-04-24 | 2018-09-28 | 国立大学法人九州大学 | 眼底疾病治疗剂 |
| WO2014177699A1 (en) * | 2013-05-03 | 2014-11-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Rhoa (rock) inhibitors for the treatment of enflammatory bowel disease |
| AU2014274660B2 (en) | 2013-06-06 | 2019-05-16 | Pierre Fabre Médicament | Anti-C10orf54 antibodies and uses thereof |
| RU2699289C2 (ru) | 2013-08-26 | 2019-09-04 | Байонтек Рисерч Энд Дивелопмент, Инк. | НУКЛЕИНОВЫЕ КИСЛОТЫ, КОДИРУЮЩИЕ АНТИТЕЛА ПРОТИВ СИАЛИРОВАННОГО АНТИГЕНА ЛЬЮИСАа ЧЕЛОВЕКА |
| ES2966757T3 (es) | 2014-03-04 | 2024-04-24 | Fate Therapeutics Inc | Métodos de reprogramación mejorados y plataformas de cultivo celular |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| AU2015271685B2 (en) | 2014-06-04 | 2021-02-18 | Biontech Research And Development, Inc. | Human monoclonal antibodies to ganglioside GD2 |
| KR20170020527A (ko) | 2014-06-27 | 2017-02-22 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 배양된 포유동물 윤부 줄기세포, 이를 생성하는 방법, 및 이의 용도 |
| HUE052771T2 (hu) | 2014-12-11 | 2021-05-28 | Pf Medicament | C10orf54 elleni antitestek és alkalmazásuk |
| US10106525B2 (en) | 2015-01-26 | 2018-10-23 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| US10857157B2 (en) | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
| US10149856B2 (en) | 2015-01-26 | 2018-12-11 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
| EP3256164B1 (en) | 2015-02-09 | 2020-03-25 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex |
| CN114504651A (zh) | 2015-03-03 | 2022-05-17 | 科马布有限公司 | 抗体、用途和方法 |
| US20180296474A1 (en) | 2015-10-13 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
| EP4088719A1 (en) | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
| AU2016338680B2 (en) | 2015-10-16 | 2022-11-17 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
| KR20180086246A (ko) | 2015-12-02 | 2018-07-30 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도 |
| US11253590B2 (en) | 2015-12-02 | 2022-02-22 | Stsciences, Inc. | Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator) |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| US11198680B2 (en) | 2016-12-21 | 2021-12-14 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| CA3065301A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
| CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
| EP3635007A1 (en) | 2017-06-06 | 2020-04-15 | STCube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands |
| US10537567B2 (en) | 2017-07-11 | 2020-01-21 | BioAxone BioSciences, Inc. | Kinase inhibitors for treatment of disease |
| JP7256796B2 (ja) | 2017-10-13 | 2023-04-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体 |
| WO2019124488A1 (ja) | 2017-12-21 | 2019-06-27 | 参天製薬株式会社 | セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬 |
| US20230243836A1 (en) | 2018-07-20 | 2023-08-03 | Pierre Fabre Medicament | Receptor for vista |
| CA3110661A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
| UY38427A (es) | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
| CN111116555B (zh) * | 2018-10-30 | 2023-06-02 | 北京盈科瑞创新药物研究有限公司 | 一种Rho激酶抑制剂及其制备方法和应用 |
| WO2020193802A1 (en) | 2019-03-28 | 2020-10-01 | Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe | Polymeric conjugates and uses thereof |
| US20230348852A1 (en) | 2020-04-27 | 2023-11-02 | Novartis Ag | Methods and compositions for ocular cell therapy |
| CN111707831A (zh) * | 2020-07-16 | 2020-09-25 | 首都医科大学附属北京朝阳医院 | Rock激酶活性在辅助诊断sle以及评价sle病情中的应用 |
| US11918581B2 (en) | 2021-01-11 | 2024-03-05 | Incyte Corporation | Combination therapy comprising JAK pathway inhibitor and rock inhibitor |
| CN113262226B (zh) * | 2021-04-19 | 2023-05-16 | 杭州市第一人民医院 | 利舒地尔在制备细菌感染治疗药物中的应用 |
| CN118159645A (zh) | 2021-10-18 | 2024-06-07 | 埃维亚生命科学有限公司 | 组合物及使用其治疗肝纤维化的方法 |
| CA3235862A1 (en) | 2021-10-22 | 2023-04-27 | Takahiro Ochiya | Methods for making extracellular vesicles, and compositions and methods of use thereof |
| WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
| WO2023147107A1 (en) | 2022-01-31 | 2023-08-03 | Byomass Inc. | Myeloproliferative conditions |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58121278A (ja) | 1982-01-12 | 1983-07-19 | Asahi Chem Ind Co Ltd | イソキノリンスルホン酸アミド誘導体 |
| JPS57200366A (en) | 1981-06-01 | 1982-12-08 | Asahi Chem Ind Co Ltd | Isoquinoline compound |
| JPH0227992B2 (ja) | 1982-01-14 | 1990-06-20 | Asahi Kasei Kogyo Kk | Isokinorinsuruhonirukagobutsu |
| US4456757A (en) † | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
| JPS5993054A (ja) | 1982-11-18 | 1984-05-29 | Asahi Chem Ind Co Ltd | イソキノリンスルホン酸アミド誘導体 |
| JPS6081168A (ja) | 1983-10-13 | 1985-05-09 | Asahi Chem Ind Co Ltd | アミジン誘導体 |
| US4678783B1 (en) | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
| JPS61227581A (ja) | 1985-04-02 | 1986-10-09 | Asahi Chem Ind Co Ltd | 血管拡張剤 |
| JPS61152658A (ja) | 1984-12-27 | 1986-07-11 | Asahi Chem Ind Co Ltd | 置換されたイソキノリンスルホンアミド誘導体 |
| DE3583287D1 (de) † | 1984-12-27 | 1991-07-25 | Asahi Chemical Ind | Substituierte isochinolinsulfonyl-verbindungen. |
| JPH0680054B2 (ja) | 1985-06-19 | 1994-10-12 | 吉富製薬株式会社 | ピペリジン誘導体 |
| JPH062741B2 (ja) | 1985-10-29 | 1994-01-12 | 旭化成工業株式会社 | ２級のイソキノリンスルホンアミド誘導体 |
| JP2770497B2 (ja) | 1988-11-24 | 1998-07-02 | 吉富製薬株式会社 | トランス―４―アミノ（アルキル）―１―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途 |
| WO1990005723A1 (en) † | 1988-11-24 | 1990-05-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Trans-4-amino(alkyl)-1-pyridylcarbamoyl-cyclohexane compounds and their medicinal use |
| JP2720348B2 (ja) * | 1989-03-30 | 1998-03-04 | 旭化成工業株式会社 | 脳細胞機能障害改善剤 |
| JP3408546B2 (ja) * | 1991-02-19 | 2003-05-19 | 旭化成株式会社 | 抗喘息剤 |
| JP2864489B2 (ja) * | 1991-02-27 | 1999-03-03 | 吉富製薬株式会社 | 喘息治療剤 |
| WO1993005021A1 (en) | 1991-09-06 | 1993-03-18 | Yoshitomi Pharmaceutical Industries, Ltd. | 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof |
| JP3275389B2 (ja) * | 1991-09-06 | 2002-04-15 | 三菱ウェルファーマ株式会社 | ４−アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物 |
| JPH05273821A (ja) | 1992-03-24 | 1993-10-22 | Nippon Steel Corp | 静電画像形成装置 |
| JP3265695B2 (ja) * | 1992-05-12 | 2002-03-11 | 三菱ウェルファーマ株式会社 | ４−置換アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物 |
| JP2893029B2 (ja) * | 1992-08-10 | 1999-05-17 | 旭化成工業株式会社 | 心臓保護剤 |
| JPH0680569A (ja) * | 1992-09-03 | 1994-03-22 | Asahi Chem Ind Co Ltd | 血小板凝集阻害剤 |
| JP3218356B2 (ja) | 1993-03-31 | 2001-10-15 | ヤンマー農機株式会社 | 管理機 |
| JPH06289679A (ja) * | 1993-04-01 | 1994-10-18 | Hitachi Metals Ltd | 画像形成方法 |
| JP3464012B2 (ja) * | 1993-04-05 | 2003-11-05 | 旭化成株式会社 | 精神症候治療剤 |
| DE4323295C1 (de) * | 1993-07-12 | 1995-02-09 | Manfred R Dr Hamm | Dosiervorrichtung |
| JPH0741424A (ja) * | 1993-07-28 | 1995-02-10 | Asahi Chem Ind Co Ltd | 抗炎症剤 |
| JPH07277979A (ja) * | 1994-04-12 | 1995-10-24 | Asahi Chem Ind Co Ltd | 過粘性症候群治療または予防剤 |
| EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
| EP0956865B2 (en) * | 1996-08-12 | 2010-08-18 | Mitsubishi Tanabe Pharma Corporation | MEDICINES COMPRISING Rho KINASE INHIBITOR |
-
1997
- 1997-08-08 EP EP97934756A patent/EP0956865B2/en not_active Expired - Lifetime
- 1997-08-08 RU RU99104798/14A patent/RU2206321C2/ru not_active IP Right Cessation
- 1997-08-08 DK DK97934756.4T patent/DK0956865T4/da active
- 1997-08-08 CN CNB971987386A patent/CN100389828C/zh not_active Expired - Lifetime
- 1997-08-08 US US09/242,261 patent/US6218410B1/en not_active Expired - Lifetime
- 1997-08-08 JP JP50959298A patent/JP3669711B2/ja not_active Expired - Lifetime
- 1997-08-08 CZ CZ0046099A patent/CZ301044B6/cs not_active IP Right Cessation
- 1997-08-08 IL IL12845697A patent/IL128456A0/xx unknown
- 1997-08-08 DE DE69737631T patent/DE69737631T3/de not_active Expired - Lifetime
- 1997-08-08 EE EEP199900050A patent/EE9900050A/xx unknown
- 1997-08-08 AT AT97934756T patent/ATE359822T1/de active
- 1997-08-08 SI SI9730764T patent/SI0956865T2/sl unknown
- 1997-08-08 HU HU9903694A patent/HU229864B1/hu unknown
- 1997-08-08 ES ES97934756T patent/ES2286834T5/es not_active Expired - Lifetime
- 1997-08-08 KR KR1020057006623A patent/KR100595740B1/ko not_active IP Right Cessation
- 1997-08-08 WO PCT/JP1997/002793 patent/WO1998006433A1/ja active IP Right Grant
- 1997-08-08 PL PL97331561A patent/PL331561A1/xx unknown
- 1997-08-08 PT PT97934756T patent/PT956865E/pt unknown
- 1997-08-08 AU AU37851/97A patent/AU738620B2/en not_active Ceased
- 1997-08-08 BR BR9711154A patent/BR9711154A/pt not_active IP Right Cessation
- 1997-08-08 NZ NZ513800A patent/NZ513800A/xx unknown
- 1997-08-08 KR KR1019997001121A patent/KR100576148B1/ko not_active IP Right Cessation
- 1997-08-08 NZ NZ334613A patent/NZ334613A/xx unknown
- 1997-08-08 CA CA002263425A patent/CA2263425C/en not_active Expired - Lifetime
-
1999
- 1999-02-10 NO NO990622A patent/NO990622L/no not_active Application Discontinuation
- 1999-02-11 IS IS4973A patent/IS4973A/is unknown
- 1999-03-12 BG BG107195/2002A patent/BG63992B1/bg unknown
- 1999-03-12 BG BG107195/2002A patent/BG107195A/xx unknown
- 1999-03-12 BG BG103246A patent/BG63991B1/bg unknown
-
2000
- 2000-03-08 HK HK00101455A patent/HK1022436A1/xx not_active IP Right Cessation
-
2001
- 2001-02-26 US US09/791,648 patent/US6451825B1/en not_active Expired - Lifetime
-
2002
- 2002-07-31 US US10/208,100 patent/US6906061B2/en not_active Expired - Fee Related
-
2003
- 2003-02-06 RU RU2003103606/15A patent/RU2003103606A/ru not_active Application Discontinuation
- 2003-02-12 RU RU2003104284/15A patent/RU2003104284A/ru not_active Application Discontinuation
- 2003-03-19 BG BG107645/2003A patent/BG107645A/xx unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8357693B2 (en) | 2005-03-25 | 2013-01-22 | Surface Logix, Inc. | Pharmacokinetically improved compounds |
| US8916576B2 (en) | 2005-03-25 | 2014-12-23 | Surface Logix, Inc. | Pharmacokinetically improved compounds |
| US9440961B2 (en) | 2005-03-25 | 2016-09-13 | Surface Logix, Inc. | Rho-kinase inhibitors and method of preparation |
| US10570123B2 (en) | 2005-03-25 | 2020-02-25 | Surface Logix, Llc | Pharmacokinetically improved compounds |
| US11384051B2 (en) | 2015-06-24 | 2022-07-12 | Nitto Denko Corporation | Ionizable compounds and compositions and uses thereof |
| RU2776478C2 (ru) * | 2015-06-24 | 2022-07-21 | Нитто Денко Корпорейшн | Ионизируемые соединения и композиции и их применения |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2206321C2 (ru) | Фармацевтическое средство, содержащее ингибитор rho-киназы | |
| RU99104798A (ru) | Фармацевтическое средство, содержащее ингибитор rho-киназы | |
| DE69615674T2 (de) | Cyclobutan-derivate als inhibitoren der squalen-synthase und der protein farnesyltransferase | |
| MX19368A (es) | Procedimiento para la preparacion de derivados heterociclicos que contienen nitrogeno benzofusionado y compuesto obtenido. | |
| CA2443918A1 (en) | Visual function disorder improving agents containing rho kinase inhibitors | |
| NO985711D0 (no) | Farmas°ytikum for behandling av neurologiske og neuropsykiatriske mangler | |
| PT763037E (pt) | Derivados de pirrol ¬a|-anelizados e sua utilizacao farmaceutica | |
| DE60115465D1 (de) | Immunoregulierende verbindungen, deren derivate und ihre verwendung | |
| JP2001511124A (ja) | エイズ治療薬としての、プロテアーゼ阻害剤およびリバーストランスクリプターゼ阻害剤との３剤組み合わせ物におけるキノキサリン | |
| NO965444L (no) | Triterpen-derivat samt medikamentell sammensetning omfattende dette | |
| DE69925270D1 (de) | Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten | |
| ATE204868T1 (de) | 2-aryl-3-aminoaryloxynaphthylverbindungen, zwischenverbindungen, zusammensetzungen und verfahren | |
| DK488588A (da) | Sulfonamid-forbindelser, farmaceutiske praeparater indeholdende disse og anvendelse af forbindelserne til fremstilling af antiarytmiske laegemidler | |
| BR9807330A (pt) | Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo | |
| HUP0004900A2 (hu) | Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények | |
| KR950702544A (ko) | 비페닐메탄 유도체 및 이를 함유하는 약제 | |
| FR2381034A1 (fr) | Compositions pharmaceutiques analgesiques et anti-inflammatoires a base de 1,3,5-triazine | |
| KR950002761A (ko) | 강박 반응 장애 치료제 제조용으로서의 n-(피리디닐)-1h-인돌-1-아민의 용도 | |
| KR950703956A (ko) | 순환 장애 개선제[circulatory disturbance ameliorant] | |
| HUP0302255A2 (hu) | Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| SE9401965D0 (sv) | New compounds | |
| KR960021021A (ko) | 인터루킨-1β의 생성 및 종양 괴사 인자 α의 방출을 억제하기 위한 약제 | |
| ATE169014T1 (de) | Kaliumsalz eines biphenylmethanderivates und dasselbe enthaltendes medikament | |
| JP2002371014A5 (ru) | ||
| TH52956A (th) | สารผสมของ สแททิน-สารยับยั้งของ mmp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20040809 |